Nurix Therapeutics, Inc.

NRIX · Nasdaq · ·

Confronta

16,33 USD+2,8%chiusura 11 nov

Dati fino al 31 agosto 2026, dal 10-Q depositato il 13 ottobre 2026

1W: +6,7%
1M: -26,2%

Azioni Nurix Therapeutics, Inc. (NRIX) — è una buona azienda? — InspectStocks

Nurix Therapeutics, Inc.

NRIX · Nasdaq · ·

Confronta

16,33 USD+2,8%chiusura 11 nov

Dati fino al 31 agosto 2026, dal 10-Q depositato il 13 ottobre 2026

1W: +6,7%
1M: -26,2%

Keep exploring

The themes Nurix Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Come guadagna

Collaboration revenue64%
License revenue36%

Le quote di ricavo sono stime per fiscal year ended 2025-11-30, high confidence, non cifre tratte da un documento depositato.

Compete con

Che cosa vende4

Bexobrutideg (NX-5948)
An experimental oral medicine designed to make cells remove Bruton tyrosine kinase, a protein involved in some blood cancers. It is being tested in patients with blood cancers, including chronic lymphocytic leukemia.
NX-1607
An experimental oral medicine that blocks CBL-B, a cell protein that restrains immune cells. It is being tested to help immune cells attack tumors.
Zelebrudomide (NX-2127)
An experimental oral medicine designed to remove Bruton tyrosine kinase and two proteins involved in immune-cell activity. Nurix discontinued further clinical development; some patients already receiving it may continue treatment.
NX-0479 / GS-6791
A partner-developed experimental medicine designed to degrade IRAK4, a protein involved in inflammation.

Chi lo compra4

Gilead pays for research into drug candidates and may license candidates for further development.
Sanofi pays for research into drug candidates and may license candidates for further development.
Pfizer pays for research into drug candidates intended for attachment to antibodies and may license them for development.
Roche licensed bexobrutideg and shares its development and United States commercial responsibilities with Nurix.

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

1Nurix has no product-sale revenue and depends on collaboration payments, license payments, and outside financing to fund its work.
2It relies on contract manufacturers for drug ingredients and finished medicines used in clinical trials.
3It relies on outside organizations to conduct clinical trials and on pharmaceutical partners to develop or sell some licensed drug candidates.

Che cosa potrebbe andare storto

1Nurix’s drug candidates are still being tested in people; trial results, safety findings, patient enrollment, or regulatory decisions could delay or end their development.
2Because Nurix has no approved medicines for sale, its income depends on partner payments and licensing events, which can vary in timing and may not recur.
3Problems with outside manufacturers or clinical-trial contractors could interrupt drug supply or delay trials.

Bilanci completi →

Informazioni su Nurix Therapeutics, Inc.

Nurix develops experimental medicines designed to make cells remove disease-related proteins, rather than simply block them. Its discovery system uses machine learning and large chemical libraries to find starting points for drugs. Pharmaceutical partners pay for research and rights to drug candidates; Nurix also develops some candidates itself. It has no approved medicines for sale.

Sede: San Francisco, California
Fondata nel: 2009 (founding year, medium confidence)
Quotata su: Nasdaq Global Select Market
Chiusura dell'esercizio: November 30

Costruito dai documenti depositati da Nurix Therapeutics, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.